Stolte, Benjamin http://orcid.org/0000-0002-2774-067X
Nonnemacher, Michael http://orcid.org/0000-0003-1317-6120
Kizina, Kathrin
Bolz, Saskia http://orcid.org/0000-0003-1209-1715
Totzeck, Andreas
Thimm, Andreas http://orcid.org/0000-0002-7806-9919
Wagner, Bernd http://orcid.org/0000-0003-0877-6906
Deuschl, Cornelius http://orcid.org/0000-0001-9262-7289
Kleinschnitz, Christoph http://orcid.org/0000-0002-1650-8875
Hagenacker, Tim http://orcid.org/0000-0002-3631-3450
Funding for this research was provided by:
Universität Duisburg-Essen
Article History
Received: 2 March 2021
Revised: 15 April 2021
Accepted: 16 April 2021
First Online: 25 April 2021
Declarations
:
: BS received travel reimbursement and speaker honoraria from Biogen. MN declared no conflicts of interest. KK received travel reimbursement and speaker honoraria from Biogen. SB declared no conflicts of interest. ATo declared no conflicts of interest. ATh received travel reimbursement from CSL Behring. BW declared no conflicts of interest. CD declared no conflicts of interest. CK received honoraria from Biogen and Roche. TH received honoraria from Novartis, Roche and Biogen and research support from Biogen, Roche and AveXis.
: The study was approved by the Ethics Committee of the University Duisburg-Essen, Germany (approval number: 18-8071-BO) and was therefore performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.
: Written informed consent was obtained from every patient included in this study.